Design, preparation and characterization of lactoferrinloaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles as a therapeutic alternative for keratoconus treatment

<u>R. Varela-Fernández^{1,2}</u>, X. García-Otero¹, M. I. Lema-Gesto², M. González-Barcia³, and F. J. Otero-Espinar¹

1. Department of Pharmacology, Pharmacy and Pharmaceutical Technology. University of Santiago de Compostela (USC). Campus vida. Santiago de Compostela. Zip Code: 15782. Spain. francisco.otero@usc.es.

- 2. Clinical Neurosciences Group. University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS). Travesía da Choupana s/n Santiago de Compostela. Zip Code: 15706. Spain. mariaisabel.lema@usc.es.
- 3. Molecular Imaging Group. University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS). Travesía da Choupana s/n Santiago de Compostela. Zip Code: 15706. Spain.
- 4. Clinical Pharmacology Group. University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS). Travesía da Choupana s/n Santiago de Compostela. Zip Code: 15706. Spain. miguel.gonzalez.barcia@sergas.es.



UNIVERSIDAE

DE SANTIAGO

DE COMPOSTELA

Introduction and objectives

Lactoferrin has shown potential as a good therapeutic alternative in the treatment of Keratoconus [1]. Chitosan/Cyclodextrin nanoparticles as novel drug delivery systems (DDS) could successfully encapsulate hydrophobic drugs [2]. The aim of this work was based on the design, preparation, and characterization of lactoferrin-loaded CS/SBE- β -CD nanoparticles as topical ophthalmic DDS for the keratoconus treatment.



Results

Phase diagram of nanoparticle's formation and physicochemical characterization



Phase diagram formation for lactoferrin-loaded CS/SBE-β-CD nanoparticle's formation.



Changes in size and PDI values during the optimization procedure of CS/SBE- β -CD nanoparticles.

Morphological characterisation of nanoparticles

Phase diagram reveals that only CS/SBE-β-CD specific ratios lead to nanoparticle's formation. The appearance of opalescence was used as an indicator of nanoparticle formation, also confirmed by Dynamic Light Scattering (DLS).

Low amounts of initial CS/SBE- β -CD give rise to no nanoparticle's formation, while precipitation occurred when high amounts of initial compounds were used.



Methodology

Preparation of lactoferrin CS/SBE-β-CD NPs

Nanoparticles were spontaneously obtained via **ionotropic gelation**. 1 ml lactoferrin/SBE- β -CD aqueous solution was added to 3 ml CS acidic aqueous solution under magnetic stirring at room temperature.









Scanningelectronmicrographsshowthatlactoferrin-loadedCS/SBE-β-CDnanoparticleswerepredominantlyspherical inshape.

Transmission electron microscopy images indicate that **these nanosystems may have an irregular surface.**

Characterisation of lactoferrin CS/SBE-*β***-CD NPs**



Long-term stability to storage study



Loading capacity (LC)

Time (weeks)

Time (weeks)

-2 0 2 4 6 8 10 12 14 Time (weeks)

Conclusion

Lactoferrin-loaded CS/SBE- β -CD nanoparticles were proposed as a **new ocular drug delivery system** with the virtue of easy administration, prolonged drug release time, improved ocular bioavailability and reduced dosing frequency. Lactoferrin CS/SBE- β -CD nanoparticles show considerable **potential as hydrophilic drug carrier and have the capacity to deliver drugs to specific target sites**, possibly revolutionizing the Keratoconus therapy.

Bibliography

[1] Mas Tur V, MacGregor C, Jayaswal R, O'Brart D, Maycock N. A review of keratoconus: Diagnosis, pathophysiology, and genetics. Surv Ophthalmol. 2017 Dec;62(6):770–83.
[2] Jingou J, Shilei H, Weiqi L, Danjun W, Tengfei W, Yi X. Preparation, characterization of hydrophilic and hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and in vitro release study. Colloids Surf B Biointerfaces. 2011;83(1):103-7.

Imaging analysis

Size and ζ Potential

SEM and TEM analysis